B. Riley launched its coverage of Electromed (OTCQB:EMED) with a Buy recommendation and a $38 per share target, arguing that the company, being the final remaining pure-play stock in a market for a ...

DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...